NO171828C - Fremgangsmaate for fremstilling av et stabilisert farmasoeytisk preparat inneholdende en granulocyttkolonistimulerende faktor - Google Patents

Fremgangsmaate for fremstilling av et stabilisert farmasoeytisk preparat inneholdende en granulocyttkolonistimulerende faktor

Info

Publication number
NO171828C
NO171828C NO872966A NO872966A NO171828C NO 171828 C NO171828 C NO 171828C NO 872966 A NO872966 A NO 872966A NO 872966 A NO872966 A NO 872966A NO 171828 C NO171828 C NO 171828C
Authority
NO
Norway
Prior art keywords
procedure
preparation
stimulating factor
colony stimulating
stabilized pharmaceutical
Prior art date
Application number
NO872966A
Other languages
English (en)
Norwegian (no)
Other versions
NO171828B (no
NO872966D0 (no
NO872966L (no
Inventor
Minoru Machida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO872966D0 publication Critical patent/NO872966D0/no
Publication of NO872966L publication Critical patent/NO872966L/no
Publication of NO171828B publication Critical patent/NO171828B/no
Publication of NO171828C publication Critical patent/NO171828C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO872966A 1986-07-18 1987-07-16 Fremgangsmaate for fremstilling av et stabilisert farmasoeytisk preparat inneholdende en granulocyttkolonistimulerende faktor NO171828C (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948886 1986-07-18
JP16948686 1986-07-18
JP16948786 1986-07-18
JP16948986 1986-07-18

Publications (4)

Publication Number Publication Date
NO872966D0 NO872966D0 (no) 1987-07-16
NO872966L NO872966L (no) 1988-01-19
NO171828B NO171828B (no) 1993-02-01
NO171828C true NO171828C (no) 1993-05-12

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
NO872966A NO171828C (no) 1986-07-18 1987-07-16 Fremgangsmaate for fremstilling av et stabilisert farmasoeytisk preparat inneholdende en granulocyttkolonistimulerende faktor

Country Status (24)

Country Link
KR (1) KR930004597B1 (de)
CN (1) CN1033738C (de)
AT (1) AT402259B (de)
AU (1) AU611856B2 (de)
BE (1) BE1000253A3 (de)
CA (1) CA1297007C (de)
CH (1) CH671157A5 (de)
DE (1) DE3723781C2 (de)
DK (1) DK171308B1 (de)
ES (1) ES2010226A6 (de)
FR (1) FR2601591B1 (de)
GB (1) GB2193631B (de)
GR (1) GR871067B (de)
HK (1) HK64893A (de)
HU (1) HU198627B (de)
IE (1) IE60290B1 (de)
IL (1) IL83220A (de)
IT (1) IT1218927B (de)
NL (1) NL192917C (de)
NO (1) NO171828C (de)
PT (1) PT85343B (de)
SE (1) SE503312C2 (de)
SG (1) SG64393G (de)
YU (1) YU47543B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0459516A1 (de) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP3895109B2 (ja) * 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
TWI245645B (en) 1999-09-08 2005-12-21 Chugai Pharmaceutical Co Ltd Protein solution formulations and stabilization methods thereof
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
ES2220673T3 (es) * 2000-02-29 2004-12-16 Pfizer Products Inc. Factor estimulante de colonias de granulocitos estabilizado.
EP2275557A1 (de) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albuminfusionsproteine
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1930024A3 (de) * 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF Lösungsformulierung mit Langzeitstabilität
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2990417A1 (de) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin-insulin-fusionsprotein
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2094274A4 (de) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 peptid-analoga mit cxcr4 superagonisten-aktivität für knochenmarkserholung
EP2396023A2 (de) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Kurze peptide aus beta-defensin
CN102740840A (zh) 2010-01-19 2012-10-17 韩美科学株式会社 长效g-csf缀合物的液体制剂
EP2399572A1 (de) 2010-06-22 2011-12-28 Sandoz AG Langzeitaufbewahrung von nicht-glykosyliertem rekombinantem humanem G-CSF
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
EP3797752B1 (de) * 2018-05-21 2024-07-17 Chugai Seiyaku Kabushiki Kaisha In einem glasbehältnis verschlossene lyophilisierte formulierung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
AU523077B2 (en) * 1978-03-20 1982-07-08 Green Cross Corporation, The Hgi glycoprotein
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
DE3686794T2 (de) * 1985-02-05 1993-03-04 Cetus Oncology Corp Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
PT85343B (pt) 1990-04-30
GB8716904D0 (en) 1987-08-26
SG64393G (en) 1993-08-06
PT85343A (en) 1987-08-01
NL192917C (nl) 1998-05-07
KR880001297A (ko) 1988-04-22
SE8702907L (sv) 1988-01-19
NO171828B (no) 1993-02-01
GB2193631B (en) 1990-11-21
FR2601591B1 (fr) 1991-04-26
SE503312C2 (sv) 1996-05-13
DE3723781C2 (de) 1999-09-02
NO872966D0 (no) 1987-07-16
AT402259B (de) 1997-03-25
YU134287A (en) 1989-06-30
ATA177587A (de) 1996-08-15
DK368387A (da) 1988-01-19
CA1297007C (en) 1992-03-10
CN87104963A (zh) 1988-02-24
IT1218927B (it) 1990-04-24
AU611856B2 (en) 1991-06-27
NL192917B (nl) 1998-01-05
NL8701640A (nl) 1988-02-16
SE8702907D0 (sv) 1987-07-17
GR871067B (en) 1987-11-19
IL83220A0 (en) 1987-12-31
DK368387D0 (da) 1987-07-15
GB2193631A (en) 1988-02-17
HK64893A (en) 1993-07-16
IE60290B1 (en) 1994-06-29
FR2601591A1 (fr) 1988-01-22
AU7566587A (en) 1988-01-21
NO872966L (no) 1988-01-19
KR930004597B1 (ko) 1993-06-01
CN1033738C (zh) 1997-01-08
HUT44941A (en) 1988-05-30
CH671157A5 (de) 1989-08-15
YU47543B (sh) 1995-10-03
DE3723781A1 (de) 1988-01-21
IE871933L (en) 1988-01-18
HU198627B (en) 1989-11-28
IT8767594A0 (it) 1987-07-10
IL83220A (en) 1993-01-31
DK171308B1 (da) 1996-09-02
BE1000253A3 (fr) 1988-09-27
ES2010226A6 (es) 1989-11-01

Similar Documents

Publication Publication Date Title
NO171828C (no) Fremgangsmaate for fremstilling av et stabilisert farmasoeytisk preparat inneholdende en granulocyttkolonistimulerende faktor
NO863670D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat av et hydrofobt legemiddel.
NO871790D0 (no) Fremgangsmaate for fremstilling av et oralt farmasoeytisk preparat.
PT84416B (pt) Processo para a preparacao de formas de dosagem de libertacao controlada para administracao oral contendo polissacaridos de origem natural
NO169439C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxadiazoler
FI98046B (fi) Menetelmä syklosporiinia sisältävän farmaseuttisen koostumuksen valmistamiseksi
NO175286C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat som omfatter dobbeltveggede mikrokapsler
IS1530B (is) Aðferð við framleiðslu á nýjum lyfjablöndum með tempraðri losun á virka efninu
NO175515C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for perkutan tilförsel
NO170079C (no) Fremgangsmaate for fremstilling av et krystallinsk torasemid
NO934897L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO173590C (no) Fremgangsmaate for fremstilling av et stabilt nikorandilholdig farmasoeytisk preparat
NO872551D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO862141L (no) Fremgangsmaate for fremstilling av aktive cinnolinderivater
NO177485C (no) Fremgangsmåte for fremstilling av et farmasöytisk inhalasjonspreparat
PT87243A (pt) Process for the preparation of aliphatic carboxamides and of pharmaceutical compounds containing them
NO874850D0 (no) Fremgangsmaate for fremstilling av benzotiadiazinforbindelser og farmasoeytisk akseptable salter derav.
NO179396C (no) Fremgangsmåte ved fremstilling av en medikamentell administreringsform for drövtyggere
PT88682A (pt) A process for the preparation of pharmaceutical compositions containing a piperidinoalkanol-decongestant combination
PT88681A (pt) A process for the preparation of pharmaceutical compositions containing piperidinoalkanol derivatives
NO880294L (no) Fremgangsmaate for fremstilling av tetrahydrofuranderivater
NO874200D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
PT87679A (pt) A process for the preparation of 2-methoxymethyl-penem derivatives and of pharmaceutical compositions containing the same
NO170569C (no) Fremgangsmaate for fremstilling av preparat for oral dosering av etoposid
NO873423D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater

Legal Events

Date Code Title Description
MK1K Patent expired